Skip to main content
. Author manuscript; available in PMC: 2023 May 15.
Published in final edited form as: Expert Rev Anticancer Ther. 2022 Sep 19;22(10):1017–1027. doi: 10.1080/14737140.2022.2124971

Figure 1.

Figure 1.

A) ImmTAC molecules are bispecific molecules that include an antigen-binding T-cell receptor (TCR) and an anti-CD3 domain. B) The antigen-binding TCR recognizes a specific peptide-HLA complex on the target tumor cell, while the anti-CD3 fragment binds to CD3 on circulating T cells, thus redirecting and activating T cells for tumor cell killing